Mirum Pharmaceuticals, Inc. Amortization of Intangible Assets
Mirum Pharmaceuticals, Inc. (MIRM) reported Amortization of Intangible Assets of $6.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $6.70M, a 13.56% increase year-over-year.
- Mirum Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $6.80M, a 13.33% increase year-over-year.
- Mirum Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $6.00M, a 0.00% change year-over-year.
- Mirum Pharmaceuticals, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $6.00M, a 1.69% increase year-over-year.
- Mirum Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2025 was $23.90M, a 3.46% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2024 was $23.10M, a 120.00% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2023 was $10.50M, a 262.07% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. amortization of intangible assets for fiscal 2022 was $2.90M, a 866.67% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $6.70M 10-Q · filed 2026-08-05 | $13.50M 10-Q · filed 2026-08-05 | $19.50M derived: sum of 3 quarters · filed 2026-08-05 | $25.50M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $6.80M 10-Q · filed 2026-05-06 | $12.80M derived: sum of 2 quarters · filed 2026-05-06 | $18.80M derived: sum of 3 quarters · filed 2026-05-06 | $24.70M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.00M derived: sum of 2 quarters · filed 2026-02-25 | $17.90M derived: sum of 3 quarters · filed 2026-08-05 | $23.90M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $6.00M 10-Q · filed 2025-11-04 | $11.90M derived: sum of 2 quarters · filed 2026-08-05 | $17.90M 10-Q · filed 2025-11-04 | $23.90M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $5.90M 10-Q · filed 2026-08-05 | $11.90M 10-Q · filed 2026-08-05 | $17.90M derived: sum of 3 quarters · filed 2026-08-05 | $23.80M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $6.00M 10-Q · filed 2026-05-06 | $12.00M derived: sum of 2 quarters · filed 2026-05-06 | $17.90M derived: sum of 3 quarters · filed 2026-05-06 | $23.60M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.90M derived: sum of 2 quarters · filed 2026-02-25 | $17.60M derived: sum of 3 quarters · filed 2026-02-25 | $23.10M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $5.90M 10-Q · filed 2025-11-04 | $11.60M derived: sum of 2 quarters · filed 2025-11-04 | $17.10M 10-Q · filed 2025-11-04 | $22.50M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $5.70M 10-Q · filed 2025-08-06 | $11.20M 10-Q · filed 2025-08-06 | $16.60M derived: sum of 3 quarters · filed 2026-02-25 | $19.20M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $5.50M 10-Q · filed 2025-05-07 | $10.90M derived: sum of 2 quarters · filed 2026-02-25 | $13.50M derived: sum of 3 quarters · filed 2026-02-25 | $14.80M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $8.00M derived: sum of 2 quarters · filed 2026-02-25 | $9.30M derived: sum of 3 quarters · filed 2026-02-25 | $10.50M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $2.60M 10-Q · filed 2024-11-12 | $3.90M derived: sum of 2 quarters · filed 2024-11-12 | $5.10M 10-Q · filed 2024-11-12 | $6.30M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $1.30M 10-Q · filed 2024-08-07 | $2.50M 10-Q · filed 2024-08-07 | $3.70M derived: sum of 3 quarters · filed 2025-02-26 | $4.70M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $1.30M 10-Q · filed 2024-05-08 | $2.40M derived: sum of 2 quarters · filed 2025-02-26 | $3.40M derived: sum of 3 quarters · filed 2025-02-26 | $3.90M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.10M derived: sum of 2 quarters · filed 2025-02-26 | $2.60M derived: sum of 3 quarters · filed 2025-02-26 | $2.90M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $1.00M 10-Q · filed 2023-11-02 | $1.50M derived: sum of 2 quarters · filed 2023-11-02 | $1.80M 10-Q · filed 2023-11-02 | $2.10M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-06-30 | $500.00K 10-Q · filed 2023-08-07 | $800.00K 10-Q · filed 2023-08-07 | $1.10M derived: sum of 3 quarters · filed 2024-03-15 | $1.10M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-03-31 | $300.00K 10-Q · filed 2023-05-04 | $300.00 10-Q · filed 2022-05-05 | $600.00K derived: sum of 2 quarters · filed 2024-03-15 | $600.00K derived: sum of 3 quarters · filed 2024-03-15 | $600.00K derived: sum of 4 quarters · filed 2024-03-15 |
| 2021-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $300.00K derived: sum of 2 quarters · filed 2024-03-15 | $300.00K derived: sum of 3 quarters · filed 2024-03-15 | $300.00K 10-K · filed 2024-03-15 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |